 David Saxon
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertriglyceridemia | 2 | 2024 | 39 | 1.070 |
Why?
| | Remote Consultation | 3 | 2021 | 54 | 0.940 |
Why?
| | Anti-Obesity Agents | 3 | 2021 | 57 | 0.790 |
Why?
| | General Practice | 1 | 2023 | 29 | 0.790 |
Why?
| | Veterans | 4 | 2024 | 1476 | 0.730 |
Why?
| | Metabolic Syndrome | 2 | 2020 | 354 | 0.690 |
Why?
| | Weight Loss | 3 | 2024 | 787 | 0.680 |
Why?
| | Obesity | 6 | 2024 | 2992 | 0.670 |
Why?
| | Medicine | 1 | 2021 | 121 | 0.610 |
Why?
| | Insulinoma | 1 | 2018 | 26 | 0.580 |
Why?
| | Confusion | 1 | 2018 | 28 | 0.580 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 117 | 0.570 |
Why?
| | Cardiology | 1 | 2020 | 274 | 0.550 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2025 | 2531 | 0.550 |
Why?
| | Quality Improvement | 1 | 2024 | 1178 | 0.500 |
Why?
| | Delivery of Health Care | 2 | 2021 | 951 | 0.480 |
Why?
| | Insulin Antibodies | 1 | 2016 | 105 | 0.480 |
Why?
| | Hypercholesterolemia | 1 | 2016 | 106 | 0.470 |
Why?
| | Rituximab | 1 | 2016 | 176 | 0.460 |
Why?
| | Cognition Disorders | 1 | 2018 | 496 | 0.430 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 250 | 0.430 |
Why?
| | Immunologic Factors | 1 | 2016 | 236 | 0.430 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 445 | 0.370 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 460 | 0.370 |
Why?
| | Referral and Consultation | 3 | 2023 | 786 | 0.360 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2111 | 0.360 |
Why?
| | Hypoglycemia | 1 | 2016 | 445 | 0.350 |
Why?
| | Hypoglycemic Agents | 3 | 2022 | 1291 | 0.340 |
Why?
| | Pancreatic Neoplasms | 1 | 2018 | 938 | 0.330 |
Why?
| | Blood Glucose | 4 | 2025 | 2186 | 0.310 |
Why?
| | Primary Health Care | 3 | 2024 | 1738 | 0.260 |
Why?
| | Humans | 28 | 2025 | 137585 | 0.250 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2025 | 641 | 0.240 |
Why?
| | Life Style | 2 | 2021 | 490 | 0.230 |
Why?
| | Insulin | 1 | 2016 | 2409 | 0.230 |
Why?
| | Gastric Balloon | 1 | 2024 | 17 | 0.220 |
Why?
| | Neural Stem Cells | 2 | 2023 | 156 | 0.220 |
Why?
| | Osteoporotic Fractures | 1 | 2025 | 60 | 0.220 |
Why?
| | Basolateral Nuclear Complex | 1 | 2023 | 11 | 0.220 |
Why?
| | Secondary Prevention | 1 | 2025 | 233 | 0.210 |
Why?
| | Pancreatitis | 1 | 2024 | 134 | 0.210 |
Why?
| | Glucagon-Like Peptides | 1 | 2024 | 58 | 0.210 |
Why?
| | Veterans Health | 2 | 2021 | 186 | 0.190 |
Why?
| | Osteoporosis | 1 | 2025 | 243 | 0.190 |
Why?
| | Telephone | 1 | 2023 | 173 | 0.190 |
Why?
| | Male | 14 | 2025 | 67762 | 0.180 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.180 |
Why?
| | Chylomicrons | 1 | 2021 | 9 | 0.180 |
Why?
| | Pastoral Care | 1 | 2021 | 2 | 0.180 |
Why?
| | Humanism | 1 | 2021 | 6 | 0.180 |
Why?
| | Cohort Studies | 3 | 2021 | 5742 | 0.170 |
Why?
| | Adult | 10 | 2025 | 37929 | 0.170 |
Why?
| | Behavior Therapy | 2 | 2021 | 264 | 0.170 |
Why?
| | Capacity Building | 1 | 2021 | 63 | 0.170 |
Why?
| | Transgender Persons | 1 | 2023 | 186 | 0.160 |
Why?
| | Middle Aged | 8 | 2025 | 33479 | 0.160 |
Why?
| | PPAR gamma | 1 | 2021 | 182 | 0.160 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1040 | 0.160 |
Why?
| | Specialization | 1 | 2021 | 144 | 0.160 |
Why?
| | Feeding Behavior | 1 | 2005 | 654 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 214 | 0.160 |
Why?
| | Mutagenesis, Insertional | 1 | 2019 | 65 | 0.160 |
Why?
| | Gene Targeting | 1 | 2019 | 81 | 0.160 |
Why?
| | Physicians, Primary Care | 2 | 2021 | 236 | 0.150 |
Why?
| | Transgenes | 1 | 2019 | 180 | 0.150 |
Why?
| | History, 21st Century | 1 | 2019 | 213 | 0.150 |
Why?
| | Metformin | 1 | 2022 | 331 | 0.150 |
Why?
| | Genetic Loci | 1 | 2019 | 288 | 0.140 |
Why?
| | Safety-net Providers | 1 | 2019 | 119 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2021 | 512 | 0.140 |
Why?
| | Counseling | 1 | 2021 | 391 | 0.140 |
Why?
| | Female | 12 | 2025 | 73304 | 0.140 |
Why?
| | Hypolipidemic Agents | 1 | 2018 | 91 | 0.140 |
Why?
| | Pandemics | 2 | 2023 | 1639 | 0.130 |
Why?
| | Colorado | 2 | 2024 | 4565 | 0.130 |
Why?
| | Aged | 6 | 2025 | 23961 | 0.130 |
Why?
| | Telemedicine | 2 | 2025 | 862 | 0.130 |
Why?
| | Urban Population | 1 | 2019 | 479 | 0.130 |
Why?
| | Medication Therapy Management | 1 | 2016 | 76 | 0.120 |
Why?
| | Glioma | 1 | 2019 | 395 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2021 | 10811 | 0.110 |
Why?
| | Elementary Particles | 1 | 2014 | 12 | 0.110 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 494 | 0.110 |
Why?
| | Exercise | 1 | 2005 | 2057 | 0.110 |
Why?
| | Quantum Theory | 1 | 2014 | 78 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 698 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2018 | 1046 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2014 | 578 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 3958 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2691 | 0.070 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2007 | 11 | 0.070 |
Why?
| | Neurologic Examination | 1 | 2007 | 110 | 0.060 |
Why?
| | Diabetic Neuropathies | 1 | 2007 | 94 | 0.060 |
Why?
| | Diet, Atherogenic | 1 | 2005 | 6 | 0.060 |
Why?
| | United States | 2 | 2020 | 14841 | 0.060 |
Why?
| | Diphosphonates | 1 | 2025 | 66 | 0.060 |
Why?
| | Bone Density Conservation Agents | 1 | 2025 | 80 | 0.060 |
Why?
| | Accidental Falls | 1 | 2025 | 196 | 0.050 |
Why?
| | Amygdala | 1 | 2023 | 191 | 0.050 |
Why?
| | Time | 1 | 2021 | 83 | 0.040 |
Why?
| | Affect | 1 | 2023 | 292 | 0.040 |
Why?
| | Diet, Reducing | 1 | 2021 | 89 | 0.040 |
Why?
| | Weight Gain | 1 | 2024 | 519 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 117 | 0.040 |
Why?
| | Homozygote | 1 | 2021 | 203 | 0.040 |
Why?
| | Electronics | 1 | 2021 | 76 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 186 | 0.040 |
Why?
| | Efficiency | 1 | 2021 | 99 | 0.040 |
Why?
| | Heterozygote | 1 | 2021 | 293 | 0.040 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 82 | 0.040 |
Why?
| | Recombinases | 1 | 2019 | 6 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 318 | 0.040 |
Why?
| | Ambulatory Care Facilities | 1 | 2022 | 232 | 0.040 |
Why?
| | Pedigree | 1 | 2021 | 514 | 0.040 |
Why?
| | Health Care Reform | 1 | 2021 | 107 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 147 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 217 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 15657 | 0.040 |
Why?
| | Self Report | 1 | 2023 | 827 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5778 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 283 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2021 | 451 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 10388 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1236 | 0.030 |
Why?
| | Bariatric Surgery | 1 | 2021 | 217 | 0.030 |
Why?
| | Rural Population | 1 | 2022 | 563 | 0.030 |
Why?
| | Schools | 1 | 2021 | 461 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 945 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 730 | 0.030 |
Why?
| | Curriculum | 1 | 2023 | 992 | 0.030 |
Why?
| | Endocrinology | 1 | 2016 | 79 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1020 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1477 | 0.030 |
Why?
| | Neurons | 1 | 2023 | 1590 | 0.030 |
Why?
| | Mice | 2 | 2023 | 17787 | 0.030 |
Why?
| | Mesons | 1 | 2014 | 9 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 530 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 806 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2167 | 0.030 |
Why?
| | Electrons | 1 | 2014 | 83 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2021 | 986 | 0.030 |
Why?
| | Adolescent | 2 | 2023 | 21513 | 0.020 |
Why?
| | Comorbidity | 1 | 2018 | 1622 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2426 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3412 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.020 |
Why?
| | Animals | 2 | 2023 | 36940 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5757 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5472 | 0.020 |
Why?
| | Sensory Thresholds | 1 | 2007 | 26 | 0.020 |
Why?
| | Infant | 1 | 2021 | 9465 | 0.020 |
Why?
| | Diabetic Foot | 1 | 2007 | 24 | 0.020 |
Why?
| | Vibration | 1 | 2007 | 72 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11074 | 0.020 |
Why?
| | Child | 1 | 2021 | 21935 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 3284 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2007 | 3715 | 0.010 |
Why?
|
|
Saxon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|